SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.54 CNY | -1.26% |
|
+0.48% | -37.27% |
| Sales 2022 | 174M 24M 1.9B | Sales 2023 | 190M 26.19M 2.07B | Capitalization | 2.16B 298M 23.55B |
|---|---|---|---|---|---|
| Net income 2022 | 64M 8.81M 697M | Net income 2023 | 38M 5.23M 414M | EV / Sales 2022 | 7.82 x |
| Net cash position 2022 | 920M 127M 10.01B | Net cash position 2023 | 861M 119M 9.37B | EV / Sales 2023 | 6.85 x |
| P/E ratio 2022 |
33.5
x | P/E ratio 2023 |
55.5
x | Employees | 321 |
| Yield 2022 |
3.56% | Yield 2023 |
1% | Free-Float | 34.18% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.26% | ||
| 1 week | +0.48% | ||
| Current month | -5.71% | ||
| 1 month | -13.70% | ||
| 3 months | -19.25% | ||
| 6 months | -36.44% | ||
| Current year | -37.27% |
1 week
12.03
12.81
1 month
11.5014.35
Current year
10.9820.65
1 year
10.9822.60
3 years
10.9862.99
5 years
10.9862.99
10 years
10.9862.99
| Managers | Title | Age | Since |
|---|---|---|---|
Tie Jiong Fan
CEO | Chief Executive Officer | 39 | 13/08/15 |
Yi Ming He
BRD | Director/Board Member | 69 | 13/08/15 |
Qiong Cheng
SEC | Corporate Secretary | 48 | 13/08/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yan Ping Jin
BRD | Director/Board Member | 69 | 13/08/15 |
Zhi He Fan
CHM | Chairman | 64 | 31/10/99 |
Tie Jiong Fan
CEO | Chief Executive Officer | 39 | 13/08/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/06/24 | 12.54 | -1.26% | 699 857 |
| 20/06/24 | 12.7 | +2.50% | 1,565,515 |
| 19/06/24 | 12.39 | +0.32% | 529,750 |
| 18/06/24 | 12.35 | +2.07% | 516,190 |
| 17/06/24 | 12.1 | -1.06% | 404,064 |
End-of-day quote Shanghai S.E., June 20, 2024
More quotes
Shanghai Serum Bio-Technology Co Ltd is a China-based company mainly engaged in the research and development of antisera and antitoxins. The Company is mainly engaged in the research, development, manufacturing and sales of preventive and therapeutic drugs in the field of biotoxins and biosafety. The Company's main products include anti-pit viper venom, anti-five-step snake venom, anti-bungi venom, anti-cobra venom, equine immunoglobulin and anti-rabies serum. The Company's products are mainly used for emergency snakebite treatment. The Company mainly conducts its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
27/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -37.27% | 189M | |
| +2.22% | 93.53B | |
| -1.32% | 38.27B | |
| -13.44% | 32.84B | |
| +76.30% | 27.83B | |
| -13.11% | 16.08B | |
| +0.68% | 14.02B | |
| -12.06% | 11.47B | |
| +185.28% | 9.92B | |
| -53.00% | 9.42B |
- Stock Market
- Equities
- 688163 Stock
